Target Validation Information
Target ID T56625
Target Name Tripeptidyl-peptidase II
Target Type
Discontinued
Drug Potency against Target UCL-2000 and butabindide Drug Info IC50 = 7 nM [552316]
(2S)-aminobutyryl-L-proline n-pentylamide Drug Info Ki = 270 nM [527857]
L-leucyl-L-prolinamide Drug Info Ki = 2100 nM [527857]
Alpha-methylalanyl-L-proline butylamide Drug Info Ki = 5000 nM [527857]
(2S)-aminobutyryl-L-prolinamide Drug Info Ki = 570 nM [527857]
L-norleucyl-L-prolinamide Drug Info Ki = 2000 nM [527857]
(2S)-aminobutyryl-(R)-pipecolinic acid amide Drug Info Ki = 12000 nM [527857]
L-valyl-L-prolinamide Drug Info Ki = 6000 nM [527857]
(2S)-aminobutyryl-L-proline (R)-sec-butylamide Drug Info Ki = 4500 nM [527857]
(2S)-aminobutyryl-L-proline n-propylamide Drug Info Ki = 80 nM [527857]
L-isoleucyl-L-prolinamide Drug Info Ki = 4300 nM [527857]
(2S)-aminobutyryl-L-proline n-butylamide Drug Info Ki = 80 nM [527857]
L-valyl-L-proline benzylamide Drug Info Ki = 3300 nM [527857]
L-valyl-L-proline hexylamide Drug Info Ki = 900 nM [527857]
L-norvalyl-L-prolinamide Drug Info Ki = 1600 nM [527857]
(2S)-aminobutyryl-L-proline isobutylamide Drug Info Ki = 320 nM [527857]
(2S)-aminobutyryl-L-proline-(2S)-methylbutylamide Drug Info Ki = 500 nM [527857]
References
Ref 552316Design, synthesis, and tripeptidyl peptidase II inhibitory activity of a novel series of (S)-2,3-dihydro-2-(4-alkyl-1H-imidazol-2-yl)-1H-indoles. J Med Chem. 2002 Nov 21;45(24):5303-10.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ref 527857J Med Chem. 2005 Nov 17;48(23):7333-42.Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.